Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 nov. 2022 04h00 HE
|
Sol-Gel Technologies Ltd.
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel’s cash runway expected to extend through the end of the first quarter of 2024NESS ZIONA,...
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
03 oct. 2022 08h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 août 2022 06h00 HE
|
Sol-Gel Technologies Ltd.
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA...
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
01 juin 2022 08h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
17 mai 2022 07h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
13 mai 2022 07h00 HE
|
Sol-Gel Technologies Ltd.
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two...
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
25 avr. 2022 07h00 HE
|
Sol-Gel Technologies Ltd.
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma...
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
14 avr. 2022 08h30 HE
|
Sol-Gel Technologies Ltd.
TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acneSol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO® in the U.S. at the Annual Meeting of the...
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
30 mars 2022 07h00 HE
|
Sol-Gel Technologies Ltd.
Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022.2021 revenue of $31.3...
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
25 mars 2022 11h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and...